| Expression pattern: |
DN |
| Associated gene: |
PHLPP2 |
| Associated microRNA: |
miR-543 |
| Biological function: |
Enforced expression of circ_0001017 impeded growth, metastasis, migration, invasion, cell cycle progression and EMT, enhanced apoptosis, and sensitized cisplatin-resistant gastric cancer cells to CDDP in vitro and in vivo. |
| Molecular mechanism: |
circ_0001017 functions as a miR-543 sponge and controls PHLPP2 expression through miR-543, thereby regulating malignant behaviors and CDDP sensitivity of CDDP-resistant gastric cancer cells. |
| Biological pathway or process: |
proliferation (inhibits); cell cycle (inhibits); apoptosis (promotes); migration (inhibits); invasion (inhibits); metastasis (inhibits); EMT (inhibits); drug resistance (inhibits); chemoresistance (inhibits); ceRNA regulation (other) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; RNase R Treatment; Clinical Sample Validation; Bioinformatics Analysis; Luciferase Reporter Assay; RIP (RNA Immunoprecipitation); Transfection; CCK8; Colony Formation Assay; Cell Cycle Assay; Annexin V/PI Flow Cytometry; Transwell Assay; Western Blot; In Vivo Animal Model |
| Clinical significance: |
Low expression of circ_0001017 was associated with CDDP resistance of GC, and circ_0001017 was proposed as a potential therapeutic agent against CDDP-resistant GC. |
| Description: |
circ_0001017 is downregulated in cisplatin-resistant gastric cancer tissues and cell lines. Its enforced expression suppresses malignant phenotypes and EMT, promotes apoptosis, and increases cisplatin sensitivity by sponging miR-543 and upregulating PHLPP2, supporting its potential therapeutic relevance in CDDP-resistant GC. |
| Confidence score: |
0.7597 |